References
- Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabet Res Clin Pract. 2022 Jan;183:109119.
- Hakkola J, Hukkanen J, Turpeinen M, et al. Inhibition and induction of CYP enzymes in humans: an update. Arch Toxicol. 2020 Nov 01;94(11):3671–3722. doi: 10.1007/s00204-020-02936-7
- Powell NR, Liang T, Ipe J, et al. Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease. Nat Commun. 2023 Mar 17;14(1):1474. doi: 10.1038/s41467-023-37209-1
- Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022 Apr 01;10(4):284–296. doi: 10.1016/S2213-8587(22)00003-1
- Villemure S, Trenaman SC, Goralski KB. The impact of COVID-19 infection on cytochrome P450 3A4-mediated drug metabolism and drug interactions. Expert Opin Drug Metab Toxicol. 2023 Jun 03;19(6):329–332
- Gravel S, Chiasson JL, Turgeon J, et al. Modulation of CYP450 activities in patients with type 2 diabetes. Clin Pharmacol Ther. 2019 Dec;106(6):1280–1289. doi: 10.1002/cpt.1496
- Neyshaburinezhad N, Shirzad N, Rouini M, et al. Evaluation of important human CYP450 isoforms and P-glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after intensifying treatment regimen using Geneva cocktail. Basic Clin Pharmacol Toxicol. 2023;132(6):485–497. doi: 10.1111/bcpt.13840
- Kvitne KE, Åsberg A, Johnson LK, et al. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity. Clin Transl Sci. 2022;15(11):2685–2696. doi: 10.1111/cts.13394
- Jamwal R, de la Monte SM, Ogasawara K, et al. Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver. Mol Pharm. 2018 Jul 2;15(7): 2621–2632. 10.1021/acs.molpharmaceut.8b00159
- Krogstad V, Peric A, Robertsen I, et al. Correlation of body weight and composition with hepatic activities of cytochrome P450 enzymes. J Pharm Sci. 2021 Jan;110(1):432–437. doi: 10.1016/j.xphs.2020.10.027
- Zarezadeh M, Saedisomeolia A, Shekarabi M, et al. The effect of obesity, macronutrients, fasting and nutritional status on drug-metabolizing cytochrome P450s: a systematic review of current evidence on human studies. Eur J Nutr. 2021 Sep 01;60(6):2905–2921. doi: 10.1007/s00394-020-02421-y
- Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019 Oct 01;71(4):793–801. doi: 10.1016/j.jhep.2019.06.021
- Aitken AE, Richardson TA, Morgan ET. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu Rev Pharmacol Toxicol. 2006;46(1):123–149. doi: 10.1146/annurev.pharmtox.46.120604.141059
- Lenoir C, Terrier J, Gloor Y, et al. Impact of SARS-CoV-2 infection (COVID-19) on cytochromes P450 activity assessed by the Geneva cocktail. Clin Pharmacol Ther. 2021;110(5):1358–1367. doi: 10.1002/cpt.2412
- Schuette C, Steffens D, Witkowski M, et al. The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study. Cardiovasc Diabetol. 2015 Feb 3;14(1):15. doi: 10.1186/s12933-015-0182-7
- Chow E, Poon EWM, Fok BSP, et al. CYP2C19*2 polymorphism is associated with impaired oral clearance of gliclazide in healthy Chinese. Pharmgenomics Pers Med. 2019;12:397–401. doi: 10.2147/PGPM.S226200
- DeFronzo RA, Stonehouse AH, Han J, et al. Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med. 2010 Mar;27(3):309–317. doi: 10.1111/j.1464-5491.2010.02941.x
- Newman CB, Preiss D, Tobert JA, et al. Statin safety and associated adverse events: a scientific statement from the American heart association. Arterioscler Thromb Vasc Biol. 2019 Feb;39(2):e38–e81. doi: 10.1161/ATV.0000000000000073